Boost Epi-On™ Corneal Cross-Linking Data to Be Presented at the 37th Congress of the ESCRS
September 11 2019 - 4:30PM
Avedro, Inc. (Nasdaq: AVDR) (Avedro), today announced the inclusion
of a wide array of Boost Epi-On cross-linking (CXL) presentations
in the scientific and educational programs at the 10th EU Cornea
Congress and the 37th Congress of the European Society of Cataract
and Refractive Surgeons (ESCRS). These presentations will unveil
the early clinical experiences of several clinicians from multiple
geographies who have evaluated the company’s next-generation
corneal cross-linking treatment for keratoconus, a debilitating eye
disease that, if left untreated, can lead to loss of vision and
even blindness and is one of the leading causes of corneal
transplant (penetrating keratoplasty) globally.1
Boost Epi-On CXL, a novel non-invasive corneal cross-linking
procedure that does not require removal of the epithelium, the
outermost layer of the eye, addresses the limitations of prior
epi-on procedures through the addition of supplemental oxygen.
Supplemental oxygen drives oxygen diffusion across the epithelium
to enhance cross-linking which stabilizes and strengthens the
cornea, ultimately halting or slowing disease progression. Avedro
is conducting a pivotal Phase 3 clinical trial to evaluate a
similar version of the Epi-On procedure in the United States for
the treatment of progressive keratoconus. Enrollment was completed
earlier this year.
“We believe that Boost Epi-On will increase adoption of
cross-linking outside the United States because the application
will appeal to patients and clinicians seeking a non-invasive
procedure for keratoconus,” said Reza Zadno, PhD, Chief Executive
Officer of Avedro. “What’s more, we believe the scientific
presentations, coupled with Avedro’s programs at ESCRS, provide an
ideal venue to educate ophthalmologists on this new
technology.”
Physicians attending EU Cornea and ESCRS, held on September
14-18 in Paris, France, will have numerous opportunities to learn
how Boost Epi-On CXL may benefit patients and ophthalmology
practices. Clinical efficacy data and pre-clinical research will be
presented during the main scientific program, and Avedro will also
host a series of peer-to-peer group discussions and a satellite
symposium. The full event schedule is below.
Relevant Avedro Activities at
ESCRS
Friday, September 13
- 12:15 – 12:30 PM – Advances in Cross-Linking: Epi-On
Cross-Linking with Supplemental Oxygen Francois Malecaze,
PhD, Room: North 4
- 7:05 – 7:12 PM – Epi-On Epi-Off Debate in the Advent of
New Technologies Miltos Balidis, MD, Room West 3/Level
7.3
- 7:12 – 7:19 PM – A Prospective Study on Epi-On CXL
Using Supplemental Oxygen Francois Malecaze, MD, PhD, Room
West 3/Level 7.3
Saturday, September 14
- 10:00 – 10:30 AM – Boost Epi-On Meet the
Experts Miltos Balidis, MD, PhD, Avedro Booth B100
- 3:00 – 3:30 PM – Boost Epi-On Meet the Experts
Miguel Rechichi, MD, PhD, Avedro Booth B100
- 6:00 – 7:45 PM – ESCRS Satellite Symposium: Beyond
Barriers: Boost Epi-On CXL with Oxygen Cosimo Mazzota, MD,
PhD, Miltos Balidis, MD, PhD, Francois Malecaze, MD, PhD, Brendan
Cronin, MD, and Raj Rajpal as moderator. Reception and Program at
Paris Expo, Porte de Versailles – West 6 (ESCRS Congress
Venue).
Sunday, September 15
- 2:00 – 2:30 PM – Boost Epi-On Meet the Experts
Brendan Cronin, MD, Avedro Booth B100
Monday, September 16
- 4:18 – 4:24 PM – Impact of Oxygen, UV parameters and
Drug Formulation on Accelerated Epi-On Corneal
Cross-Linking Desmond Adler, PhD, Abstract Room South
5
For more information, visit Avedro booth #B100 at ESCRS.
About Avedro, Inc.Avedro is a leading
commercial-stage ophthalmic medical technology company focused on
treating corneal ectatic disorders and improving vision to reduce
dependency on eyeglasses or contact lenses. Avedro’s proprietary
Avedro Corneal Remodeling Platform is designed to strengthen,
stabilize and reshape the cornea utilizing corneal cross-linking in
minimally invasive and non-invasive outpatient procedures to treat
corneal ectatic disorders and correct refractive conditions. The
Avedro Corneal Remodeling Platform is comprised of Avedro’s KXL and
Mosaic systems, each of which delivers ultraviolet A light, and a
suite of proprietary single-use riboflavin drug formulations,
which, when applied together to the cornea, induce a biochemical
reaction called corneal collagen cross-linking.
Forward-Looking StatementsThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including, but
are not limited to, statements about the market opportunity for the
Avedro Corneal Remodeling Platform and the rate of adoption of FDA
approved cross-linking procedures. Words such as “anticipates,”
“believes,” “expects,” “intends,” “projects,” “anticipates,” and
“future” or similar expressions are intended to identify
forward-looking statements. Any forward-looking statements are
based on management’s current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. For a
discussion of risks and uncertainties and other important factors,
any of which could cause Avedro’s actual results to differ from
those contained in the forward-looking statements, see the section
titled “Risk Factors” in Avedro’s prospectus dated February 13,
2019 filed pursuant to Rule 424(b)(4) as well as discussions of
potential risks, uncertainties and other important factors in
Avedro’s subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and Avedro undertakes no duty to update this
information unless required by law.
References:
-
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2474372
Avedro Contact: |
Media Contact: |
David Iannetta |
Brian Johnston or Lynn Lewis |
781-768-3400 |
415-937-5400 |
info@avedro.com |
investors@avedro.com |
Avedro (NASDAQ:AVDR)
Historical Stock Chart
From Jul 2024 to Jul 2024
Avedro (NASDAQ:AVDR)
Historical Stock Chart
From Jul 2023 to Jul 2024